Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LNPEP | Q9UIQ6 | 7/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | ERAP2 | Q6P179 | 5/20 | 0.51 |
| ▸ | ERAP1 | Q9NZ08 | 4/20 | 0.51 |
| ▸ | TYMS | P04818 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.49 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | GLA | P06280 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3975596 | 1.00 | LNPEP (0.60) | LNPEPHDAC1HDAC6RAB9AGAA | |
| SCHEMBL11907457 | 0.93 | LNPEP (0.67) | LNPEPRAB9AGAACA2ERAP2 | |
| SCHEMBL7511243 | 0.88 | LNPEP (0.76) | LNPEPRAB9AGAACA2ERAP2 | |
| SCHEMBL7511247 | 0.88 | LNPEP (0.76) | LNPEPRAB9AGAACA2ERAP2 | |
| SCHEMBL9088699 | 0.87 | RAB9A (0.71) | LNPEPRAB9AGAACA2ERAP2 | |
| SCHEMBL9088697 | 0.87 | RAB9A (0.71) | LNPEPRAB9AGAACA2ERAP2 | |
| SCHEMBL7613514 | 0.87 | RAB9A (0.64) | LNPEPRAB9AGAACA2ERAP2 | |
| SCHEMBL16846615 | 0.86 | LNPEP (0.59) | LNPEPRAB9AGAACA2ERAP2 | |
| SCHEMBL11926971 | 0.85 | LNPEP (0.58) | LNPEPRAB9AGAACA2ERAP2 | |
| SCHEMBL7905129 | 0.85 | LNPEP (0.57) | LNPEPRAB9AGAACA2ERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2005014532-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | EPOR, HBG2, CYP2F1 | LNPEP 1652/4885HDAC1 1936/4885HDAC6 2949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.